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Introduction: Chronic Kidney Disease 
(CKD) is common, severe and treat-
able. Its detection involves low cost tests. 
Aim: To evaluate the effect of a multi-
disciplinary (nephrologist, social worker, 
nurse, nutritionist, and psychologist) in-
tervention comparing clinical and labo-
ratory parameters in patients with CKD. 
Methods: A prospective study with 2,151 
patients attended at the State Center for 
Kidney Diseases of the Vale do Paraiba, 
São Paulo, from February 2008 to March 
2011. The kidney function was measured 
using albuminuria and estimated glo-
merular filtration rate (eGRF) using the 
MDRD formula The clinical outcomes 
were the occurrence of cardiovascular 
disease (CAD), hospitalization episodes, 
need of renal replacement therapy (RRT) 
and death. Results: Participants had a 
mean (range) age of 62 years (14-101), 
a mean follow-up of 546 days (90-1540) 
and the majority was in the stage 3 of 
CKD (59%). The most common primary 
diagnoses were hypertension (41.2%) 
and diabetes (32.4%). Mean blood pres-
sure values at the beginning and at the 
end of treatment were 143 ± 26 mmHg x 
87 ± 14 mmHg and 123 ± 16 mmHg x 79 
± 9 mmHg, respectively (p < 0.001); the 
eGRF decreased from 58.5 ± 31 ml/min. 
to 56.3 ± 23 ml/min (p < 0.01). Mean 
value of proteinuria decreased from 1.04 
± 1.44 g/day to 0.61 ± 1.12 g/day, p < 
0.001, and the fasting glicemia decreased 
from 137 ± 73 mg/dl to 116 ± 42 mg/
dl. One hundred and twenty-two patients 
(5.7%) had a CAD episode, the hospital-
ization rate was 6.6% (n = 143 patients), 
7.3% patients died (n = 156), and 1.1% 
(n = 23) patients needed to start RRT. 
The risk of cardiovascular events, hospi-
talization, or death was inversely related 
to eGRF, and the rates of these events 
were low compared with the internation-
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IntroductIon
By definition, a chronic kidney disease 
(CKD) patient is any adult aged ≥18 years 
who, for a period ≥ 3 months, has shown 
a glomerular filtration rate (GFR) < 60 
mL/(min·1.73 m2), as well as those with 
GFR > 60 mL/(min·1.73 m2) but with 
some evidence of kidney lesions (urinary 
abnormalities such as glomerular hema-
turia and/or microalbuminuria/protein-
uria, or alterations on kidney imaging 
examination).1
In the USA, the prevalence of terminal-
stage CKD rose from 10,000 in 1973 to 
547,982 in 2008, with an annual cost 
of approximately $40 billion USD and 
an annual mortality rate of approxi-
mately 25%.2 A cross-sectional analysis3 
of the National Health and Nutrition 
Examination Survey (NHANES) conduct-
ed between 1994 and 2004 revealed that 
approximately 13% of the adult popu-
lation in the USA has CKD in stage 1-4. 
Decreased renal function is linked to an 
increase in the risk of death, hospitaliza-
tions, and cardiovascular events, with 
important socioeconomic implications4. 
There are no sufficient data that can il-
lustrate the magnitude of the incidence 
and prevalence of CKD in Brazil, and 
there are no expressive data regarding 
al literature. Conclusion: The multidis-
ciplinary care with well defined targets 
is effective for the preservation of renal 
function and reduction in morbidity and 
mortality of CKD patients.
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morbidity, hospitalizations, and mortality. If we ex-
trapolate from the actual American scenario, approx-
imately 13% of the population has CKD, and it is 
estimated that approximately 16 million Brazilian in-
dividuals may be affected. According to the Brazilian 
Society of Nephrology, 92,000 patients were under-
going a chronic dialysis program in 2010, totaling an 
annual cost of more than 2 billion reais and gross an-
nual mortality rate of 18%.5
The reduction in GFR occurs at an unpredict-
able and variable speed, oscillating between < 1 and 
12 mL/(min·1.73 m2) a year, with a typically faster 
decline observed in the population with diabetic ne-
phropathy.6 Studies confirm that hypertension, hy-
perglycemia, proteinuria, and cardiovascular disease 
are strongly linked to the speed of renal function loss. 
Control of these factors can avoid and minimize glo-
merular injury, and consequently reduce morbidity, 
hospitalizations, and mortality. An important com-
ponent of this approach is renin-angiotensin system 
inhibitor therapy, with 2 objectives: reduction in pro-
teinuria and blood pressure.4,7
CKD is a common, serious, treatable disease that 
must be prevented. In the initial stages, it can be de-
tected with simple and extremely low-cost labora-
tory tests, and the treatment of underlying diseases 
can prevent or delay the evolution to more advanced 
stages of CKD, cardiovascular disease, or death.
The objective of this study was to prospectively 
assess the impact of multidisciplinary intervention 
in the progression of CKD and in outcomes such 
as cardiovascular events, hospitalizations, the need 
for renal replacement therapy (RRT), and death in 
CKD patients monitored in the region of the Vale do 
Paraíba in southeastern São Paulo (SP).
Methods
study design
The State Center for the Treatment of Kidney Disease 
of the Vale do Paraíba, SP (CETDRVP) was creat-
ed in February 2008, and assists the population of 
the southeast region of the state, including primar-
ily the metropolitan regions of Taubaté, São José dos 
Campos, and Aparecida, with an estimated popula-
tion of 2.3 million. Individuals with suspected CKD 
seek the service through referral by physicians, that 
is, usually general physicians who work in the public 
network of the region. The regulating agency for ap-
pointments for the state of São Paulo is responsible for 
scheduling initial visits. In the first visit, the patient is 
seen by a nurse, a physician, a social worker, a nutri-
tionist, and a psychologist, who record the case his-
tory and diagnosis using a specific electronic record; 
then, additional examinations are scheduled. The pa-
tient returns on a monthly basis to the same physician 
and multidisciplinary team. Anthropometric data are 
noted, blood pressure (BP) is verified, and general in-
structions regarding CKD are provided in the nursing 
visit. The recorded data are stored electronically and 
physically at the outpatient clinic, with a copy duly 
signed by the healthcare professionals.
In the initial visit at the CETDRVP, the following 
are conducted: clinical history, physical examination, 
standardized measurement of BP, body mass index 
(BMI) calculation, and laboratory tests, including 
serum creatinine and albuminuria tests. The exami-
nations are conducted at the same laboratory of the 
Regional Hospital of the Vale do Paraíba (BIOFAST), 
making use of automated and standardized dosages.8 
Multidisciplinary care is conducted on every visit and 
is given by a nurse, physician, psychologist, nutrition-
ist, and a social worker. The main interventions the 
patient undergoes include the following: BP control 
(goal: ≤ 130 × 80 mmHg), use of angiotensin-convert-
ing enzyme inhibitors (ACEI) or angiotensin receptor 
blockers (ARB), glycemic control (fasting blood glu-
cose goal < 126 mg/dL), use of statins (low-density 
lipoprotein [LDL] goal ≤ 100 mg/dL), nutritional ori-
entation with overall restriction in protein consump-
tion between 0.8 and 1 g/(kg·day) for patients starting 
at stage III of CKD, and encouragement for the adop-
tion of healthy life habits such as smoking cessation 
and practicing aerobic physical exercises on a daily 
basis.1,9
For demonstrably diabetic patients, nutritional 
orientations and optimization or initiation of hypo-
glycemic medication have been implemented. Once 
admitted to the center, the patients are prospectively 
monitored at outpatient visits or until there is the 
need for RRT (dialysis or kidney transplant), death, 
or transfer of residence to a different region. The last 
patient follow-up is confirmed with data from the re-
cord, and if necessary (when the last visit was > 3 
months previous), a phone call is made to the resi-
dence to verify the current status of the patient.
In this study, 3,158 patients that visited the 
CETDRVP between February 2008 and March 2011 
were initially assessed; among these patients, we 
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selected 2,151 patients who were prospectively moni-
tored at the center for > 3 months and confirmed to 
have undergone multidisciplinary intervention. Using 
a minimum follow-up period of 3 months with the 
team as the only criteria, 1,007 patients were exclud-
ed. All of the patients signed a free and informed con-
sent form in the beginning of the follow-up period. 
The study was submitted and approved by the Ethics 
and Research Committee of the institution.
The GFR was estimated (eGFR) using the abbrevi-
ated Modification of Diet in Renal Disease (MDRD) 
formula.10 We used the modified classification of the 
National Kidney Foundation for CKD1 with stages 
based upon the eGFR: stage 1, ≥ 90 mL/(min·1.73 
m2); stage 2, 89-60 mL/(min·1.73 m2); stage 3a, (59-
45 mL/(min·1.73 m2); stage 3b, 44-30 mL/(min·1.73 
m²); stage 4, (29-15 mL/(min·1.73 m2); and stage 5, < 
15 mL/(min·1.73 m2).
A cardiovascular event (CVE) was defined as the 
following: new or aggravated acute coronary syn-
drome, new or aggravated congestive heart failure 
(CHF), new encephalic vascular accident (EVA), and 
new obstructive arterial disease (OAD). Acute coro-
nary syndrome was defined as the occurrence of acute 
myocardial infarction or unstable angina. EVA was 
defined as an ischemic or hemorrhagic lesion diag-
nosed by a neurologist after adequate imaging exam. 
CHF was defined as left ventricle deficit confirmed by 
echocardiograms. OAD was defined as acute arterial 
thrombosis of the extremities confirmed by a vascular 
surgeon.
statistical analysis
The continuous variables have been expressed as 
mean and standard deviation, and the categorical 
variables have been described as n (%). Comparisons 
between the continuous variables at the beginning 
and at the last follow-up were conducted using the 
paired Student’s t test. The comparisons between the 
mean values of variables in groups with or without 
clinical outcomes of interest were conducted using 
the unpaired Student’s t test. The tests were 2-tailed 
and the value of p < 0.05 was defined as statisti-
cally significant. Risk calculations were conducted 
using odds ratios and respective 95% confidence 
intervals (CI) for the occurrence of death, CVE, and 
hospitalizations in relation to the stages of CKD, with 
the combined stage 1 and 2 values considered as a 
reference.
The survival analyses were conducted using the 
Kaplan-Meier method, with 3 types of outcomes con-
sidered: 1) death, with patients being censured on the 
starting date of the RRT or at the end of the follow-
up period, whichever came first; 2) need for RRT, 
with patients being censured on the date of death, or 
at the end of the follow-up period; and 3) a combina-
tion of death or need for RRT, with patients being 
censured at the end of the follow-up period. Statistical 
analysis was conducted using the Statistical Package 
for the Social Sciences (SPSS) software version 14.0 
(SPSS Inc., Chicago, IL, USA).
results
clinical and labOratOry asPects in the beginning 
and end Of the fOllOw-uP PeriOd
Table 1 describes the epidemiological characteris-
tics of the study population, which included a total of 
2,151 patients, with an average age of 62 years (mini-
mum age, 14 years; maximum age, 101 years); the 
average follow-up period was 546 days (range: 90-
1,540 days), and the female sex and white race preva-
lence was 50.6% and 78.9%, respectively. In relation 
to CKD stage, stage 3 was the most prevalent, with 
1,269 individuals (59%). The most frequent underly-
ing disease of CKD was systemic hypertension (SH), 
with 886 patients (41.2%), followed by diabetes mel-
litus (DM) at 32.4%. At admission, 773 (35.9%) 
patients made use of renin-angiotensin-aldosterone 
system inhibitors (ACEI or ARB); at the end of the 
follow-up period, the number of patients using these 
medications rose to 1,937 (90.1%; p < 0.001).
Table 2 describes some parameters of clinical and 
laboratory relevance. In the beginning and at the end 
of the follow-up period, the average BP was 143 ± 26 
mmHg × 87 ± 14 mmHg and 123 ± 16 mmHg × 79 ± 
9 mmHg, respectively (p < 0.001); the eGFR was de-
creased only by 2.2 mL/min (from 58.5 ± 31 mL/min to 
56.3 ± 23 mL/min, p < 0.01). There was a drop in the 
average value of proteinuria from 1.04 ± 1.44 g/day to 
0.61 ± 1.12 g/day (p < 0.001) in the population of 634 
patients studied for this parameter (Figure 1A); for fast-
ing blood glucose level, there was a drop in average val-
ues from 137 ± 73 mg/dL to 116 ± 42 mg/dL, while the 
BMI remained stable at 27.8 kg/m2 after intervention.
There were 936 (43.5%) patients with BP ≥ 140/90 
mmHg in the beginning and 452 (21%) at the end of 
the follow-up period. In these individuals, the average 
BP values in the beginning and at the end of follow-up 
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tAble 1 clinical and ePidemiOlOgical    
 characteristics Of the study Patients   
 (n = 2,151)
Age (years) 62 ± 16 (14-101)
Follow-up time (days) 546 ± 336
Women 1,089 (50.6)
Race
White 1,697 (78.9)
Black 274 (12.7)
Mixed 179 (8.3)
CKD Stage
1 281 (13.1)
2 330 (15.3)
3a 741 (34.4)
3b 528 (24.6)
4 234 (10.9)
5 37 (1.7)
Underlying disease
SH 886 (41.2)
DM II 670 (31.1)
UNSPEC 253 (11.8)
UROLOG 160 (7.4)
DM I 28 (1.3)
CGN 37 (1.7)
ADPKD 13 (0.6)
SLE 8 (0.4)
Other 96 (4.5)
Values expressed as mean ± SD (min-max) or n (%). CKD: 
Chronic Kidney Disease; SH: Systemic Hypertension; DM II: type 
2 Diabetes Mellitus; UNSPEC: Unspecified; UROLOG: Urological; 
DM I: type 1 Diabetes Mellitus; CGN: Chronic Glomerulonephritis; 
ADPKD: Autosomal Dominant Polycystic Kidney Disease; SLE: 
Systemic Lupus Erythematosus.
tAble 2 clinical and labOratOry data at the   
 beginning and at end Of the fOllOw-uP  
 PeriOd
mean ± SD
Before After p
Systolic BP 
(mmHg)
143 ± 26 123 ± 16 0.001
Diastolic BP 
(mmHg)
87 ± 14 79 ± 9 0.001
eGFR (mL/
(min·1.73m2)
58.5 ± 31 56.3 ± 23 0.01
Proteinuria (g/day) 1.04 ± 1.44 0.61 ± 42 0.001
Fasting glycemia 
(mg/dL)
137 ± 73 116 ± 42 0.001
BMI (kg/m2) 27.8 ± 5.8 27.8 ± 5.7 0.67
BMI: Body Mass Index; BP: Blood Pressure; eGFR: estimated 
Glomerular Filtration Rate; SD: Standard Deviation.
period were 161 ± 25 mmHg × 110 ± 10 mmHg and 
128 ± 17 mmHg × 82 ± 9 mmHg, respectively (p < 
0.001; Figure 2).
Subsequently, we analyzed the subgroup of pa-
tients with fasting blood glucose level > 126 mg/dL 
at the beginning of the follow-up period (n = 368). 
There was a significant drop in the average values of 
fasting blood glucose level in the beginning and at the 
end of the follow-up period, from 218 ± 82 mg/dL to 
137 ± 53 mg/dL (p < 0.001); proteinuria, from 1.6 ± 
1.9 g/day to 1.0 ± 1.7 g/day (p < 0.001), BP, from 143 
± 26 mmHg × 87 ± 14 mmHg to 125 ± 16 mmHg × 
79 ± 9 mmHg (p < 0.001); and eGFR, from 55 ± 23 
mL/min to 53 ± 25 mL/min (p = 0.03).
Figure 1. Average values of proteinuria at the beginning and at 
the end of the follow-up period. (A) average values of proteinuria 
(g/day) at the beginning and at the end of the follow-up period for 
the entire group (n = 634), (B) average values of proteinuria at the 
beginning and at the end of the follow-up period in patients with 
initial proteinuria > 1 g/day (n = 207).
In the patients with initial proteinuria higher than 1 
g/day, we noticed a significant drop of the average pro-
teinuria level at the end of the intervention, from 2.7 
± 1.7 g/day to 1.2 ± 1.6 g/day (p < 0.001; Figure 1B).
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Figure 2. Average values of Systolic Blood Pressure (SBP) and 
Diastolic Blood Pressure (DBP) at the beginning and at the end of 
the follow-up period (n = 2151). BP in mmHg.
clinical OutcOmes
During the follow-up period, 122 patients (5.7%) 
showed CVE, of which 66 (3.1%) had ACS, 17 
showed (0.8%) CVA, 21 (1%) showed CHF, and 18 
(0.8%) showed OAD. The odds ratio (95% CI) for 
CVE was 1.2 (1.0-1.4), 1.8 (1.3-2.6), 1.8 (1.2-2.5), and 
2.3 (2.0-6.4) for stages 3a, 3b, 4, and 5, respectively. 
The overall rate of hospitalizations was 6.6% (n = 143 
patients), which increased substantially with the pro-
gression of the CKD (Table 3 and Figure 3). The odds 
ratio (95% CI) of all-cause hospitalization was 1.4 
(1.1-1.8), 1.6 (1.3-1.9), 1.8 (1.7-2.3), and 1.9 (1.8-2.3) 
for stages 3a, 3b, 4, and 5, respectively. One hundred 
fifty-six (7.3%) deaths and 23 (1.1%) patients requir-
ing RRT were observed. The odds ratio (95% CI) for 
deaths was 2.9 (1.8-3.1), 2.9 (1.6-3.1), 3.6 (2.1-4.2), 
and 6.8 (3.5-13.2) for stages 3a, 3b, 4, and 5, respec-
tively (Table 4). We observed a 1% death rate for stage 
1, 5.1% for stage 2, 6.2% for stage 3a, 7.4% for stage 
3b, 13.7% for stage 4, and 16.2% for stage 5.
Higher values of initial systolic and diastolic BP were 
significant (p < 0.01) predictors for the need for RRT.
Subsequently, we showed the cumulative prob-
ability analyses until the occurrence of the “a priori” 
selected events in the 2,151 patients monitored in the 
study. The cumulative survival probability (± stan-
dard error) after 2 years of follow-up was 92% ± 1% 
and 84% ± 2% after 3 years (Figure 4A). The inexis-
tence of renal outcome cumulative probability (need 
for RRT) after 2 years of follow-up was 98% ± 0.4% 
and 96.5% ± 0.8% after 3 years (Figure 4B).
The cumulative probability of survival or of lack 
of a need for RRT after 2 years of follow-up was 91% 
± 1% and 82% ± 2% after 3 years (Figure 4C).
tAble 3  hOsPitalizatiOn accOrding tO chrOnic  
  Kidney disease (cKd) stage and   
  underlying disease in the 360-day  
  fOllOw-uP PeriOd (n = 2,151)
Hospitalization overall rate 143 (6.6%)
CKD stage
1 3 (1.0%)
2 17 (5.1%)
3a 46 (6.2%)
3b 39 (7.4%)
4 32 (13.7%)
5 6 (16.2%)
CKD etiology
Hypertension 45 (31.5%)
Diabetes mellitus 61 (42.7%)
Urological 16 (11.2%)
Chronic glomerulonephritis 8 (5.6%)
Graft loss 1 (0.7%)
Unspecified 11 (7.7%)
Polycystic kidneys 1 (0.7%)
dIscussIon
It has been suggested that CKD patients undergoing 
multidisciplinary follow-up in Canada showed a low-
er rate of hospitalization, lower rate of urgent RRT 
initiation, and lower treatment cost11. Adequate con-
trol of BP, smoking cessation, metabolic control, and 
decrease in proteinuria are examples of goals to be 
reached. They contribute to slowing the progression 
of CKD, and in turn reduce morbimortality12. Other 
measures are necessary, including early diagnosis, 
treatment of anemia, mineral and bone disorder, and 
metabolic acidosis, which frequently occur as CKD 
progresses.
Figure 3. Hospitalization rates for 100 patients/year, according to 
the estimated glomerular filtration rate (eGFR), n = 2,151.
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tAble 4 relative risKs (95% ci) Of all-cause death, cardiOvascular event (cve), and hOsPitalizatiOn
eGFR Death CVE Hospitalization
RR (CI 95%)
≥ 60 mL/(min·1.73 m2)* 1 1 1
45-59 mL/(min·1.73 m2) 2.9 (1.8-3.1) 1.2 (1.0-1.4) 1.4 (1.1-1.8)
30-44 mL/(min·1.73 m2) 2.9 (1.6-3.1) 1.8 (1.3-2.6) 1.6 (1.3-1.9)
15-29 mL/(min·1.73 m2) 3.6 (2.1-4.2) 1.8 (1.2-2.5) 1.8 (1.7-2.3)
< 15 mL/(min·1.73 m2) 6.8 (3.5-13.2) 2.3 (2.0-6.4) 1.9 (1.8-2.3)
* reference group (CKD stages 1 + 2). CI: Confidence Interval; RR: Relative Risk; eGFR: estimated Glomerular Filtration Rate.
The key issue is how often we are applying such 
information to improve the health of this population 
in our community. By using multidisciplinary inter-
vention, we acted on the risk factors of CKD and 
analyzed the outcomes after an average 1.5 years of 
follow-up for patients treated in inland SP. The indi-
viduals in this study were generally hypertensive, dia-
betic, elderly individuals, mostly with eGFR < 60 mL/
min, and only 36% were using ACEI or ARB at the 
beginning of the follow-up period.
The presence of albuminuria is one of the main risk 
factors for the progression of CKD and cardiovascular 
diseases. Its reduction is correlated with renal function 
stabilization.13,14 The benefit of renin-angiotensin sys-
tem inhibitor drugs was well observed in the Ramipril 
Efficacy In Nephropathy (REIN) Trial,15 in which 
patients with non-diabetic chronic nephropathy were 
randomized to ramipril or placebo treatment along 
with another antihypertensive therapy. The study was 
interrupted early in patients excreting > 3 g of protein/
day due to the significant benefits in the ramipril group 
in reducing the decline of the renal function rate (0.53 
mL/min in the ramipril group vs. 0.88 mL/(min·month) 
in the placebo group). The decrease in BP-independent 
proteinuria is associated with an additional decrease in 
the declining rate of the GFR.16,17
In our study, we obtained a significant increase in 
the use of ACEI/ARB (from 36% to 90%), decrease 
in proteinuria, and slight decrease in eGFR (2 mL/
min). In patients with initial proteinuria > 1 g/day, the 
percentage decrease of proteinuria was even higher 
(55%). In the subgroup of patients with blood glucose 
> 126 mg/dL, proteinuria decreased by approximately 
40%. Our intervention was also effective in the control 
of systolic and diastolic BP. Patients with CKD and 
diastolic BP < 90 mmHg maintain better preservation 
of the GFR than hypertensive patients.10,18,19 The 
results of the MDRD multicenter research study 
suggest that both the progression rate and the efficacy 
of antihypertensive therapy may be linked to the 
basal excretion of proteins that, in turn, is a reflection 
of the severity of glomerular injury.20 The Multiple 
Risk Factor Intervention Trial study reinforced this 
observation by concluding that higher BP levels were 
an independent risk factor for the progression of 
CKD.21
The prevalence of CVD in CKD patients, even at 
the pre-dialysis stage, is higher (10-20 times) than 
that of the overall population. Approximately 90% of 
CKD patients show left ventricular hypertrophy, and 
35% show ischemic cardiac disease. CVD is the main 
cause of morbidity and mortality, and the risk of death 
is much higher than the risk of eventually needing di-
alysis.22 In the Atherosclerosis Risk in Communities 
Study,23 the presence of CKD stages 3, 4, and 5 was 
linked to a 30% increase in the risk of CVD in rela-
tive to stages 1 and 2. In the Kaiser Permanente of 
Northern California study,4 12.3% of the individuals 
with CKD showed CVD during follow-up. In spite 
of the short observational period, only 5.7% of our 
patients showed CVE, even with the majority (80%) 
belonging to stages 3, 4, and 5 of CKD.
We can speculate that this result may reflect the 
better glycemic and pressure control, the drop in 
proteinuria levels, and the greater use of ACEI/ARB 
observed in almost all of the patients. The improve-
ment of clinical and laboratory parameters and the 
reduction of CVE that we obtained with our multi-
disciplinary intervention may likely explain the lower 
hospitalization rate per 100 patients/year when com-
pared to the USA study with CKD patients moni-
tored in California without a controlled intervention4 
(6.2% vs. 13.5%, 6.2% vs. 17.2%, 8.4% vs. 45.2%, 
9.4% vs. 86.7%, and 16.2% vs. 144.6% in stages 1 
and 2, 3a, 3b, 4, and 5, respectively).
We lack data in the Brazilian literature for a com-
parison; however, the lower number of CVE and 
lower hospitalization rate that we obtained with 
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more advanced CKD patients must have an impor-
tant impact in reducing healthcare costs to these 
patients. In 2010, in the state of SP, 2,333,179 ad-
missions took place in the Universal Health Care 
System. With the goal of creating an estimate of the 
costs avoided with the multidisciplinary intervention 
that we used, we compared the prevalence of hospi-
talizations in our study in relation to the American 
study conducted in California,4 in which there was no 
specific intervention during patient follow-up; we ob-
served that there could have been a reduction of ap-
proximately 580,000 admissions/year in the state of 
SP. Considering the value of R$ 1,160.00 as the aver-
age cost for each hospitalization within the Universal 
Health Care System,24 we would be able to save ap-
proximately R$ 670 million/year with the implemen-
tation of this type of outpatient care throughout the 
state of SP.
These estimates have limitations due to the lack of 
a national population of CKD patients to serve as a 
control and to the differences in social, demographic, 
and clinical characteristics between our population 
and the American population, as well as the American 
hospitalization patterns that have not been consid-
ered. However, these estimates serve as an example of 
the great economic impact that the implementation of 
this CKD progression prevention strategy with multi-
disciplinary care may have.
CKD coexists with serious diseases such as SH, 
DM, CVD, which partially explains the higher risk 
of death in relation to individuals with normal renal 
function. In 1 systematic review,25 the relative risk of 
death was > 1 in 93% of the studies (0.94-5.0), which 
increased exponentially as renal function decreased. 
We observed 156 deaths during the 546-day follow-
up (7.3%), and a risk of 2.9, 2.9, 3.6, and 6.8 for 
stages 3a, 3b, 4, and 5, respectively. These rates must 
take into consideration the 62-year average age of the 
patients, of which approximately 1/3 had diabetic ne-
phropathy, and 80% were in stages 3, 4, and 5 of 
CKD.
In a longitudinal study with approximately 
30,000 older patients,26 the rate of RRT requirement 
in patients at stages 2, 3, or 4 was 1.1%, 1.3%, and 
19.9%, respectively; in comparison, the mortality 
rate was 19.5%, 24.3%, and 45.7%, respectively. In 
another study with more than 12,000 elderly patients 
with diabetes (48% with GFR < 60 mL/min)27 moni-
tored for 3 years, the mortality rate was 6%, 10%, 
20%, and 30% for patients at stages 2, 3, 4, and 
5, respectively. In our 1.5-year follow-up study, we 
observed a lower rate of mortality, at 5.2%, 7.8%, 
11.5%, and 21.6% for patients at stages 2, 3, 4, and 
Figure 4. Survival curves/days: (A) survival of CKD patients 
(n = 2,151). (B) cumulative probability of not needing renal 
replacement therapy (RRT; n = 2,151). (C) cumulative survival 
probability without the need for RRT (n = 2,151).
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5, respectively. Our rate of RRT requirement was also 
lower when compared to the international literature, 
at 0.5% for patients with eGFR > 60 mL/(min·1.73 
m2), 0.5% for stage 3a, 1.2% for stage 3b, 4.6% for 
stage 4, and 11.1% for stage 5.
In conclusion, our work is the first account in the 
national literature to prospectively assess clinical indica-
tors and adverse events in CKD patients under multidis-
ciplinary intervention with a large number of patients in 
the public health system. The present study demonstrated 
the effectiveness of a multidisciplinary intervention with 
well-defined laboratory and clinical parameter goals 
while monitoring CKD patients. This type of interven-
tion may be applied to many other regions of the coun-
try, and it is expected to similarly promote a better clini-
cal and laboratory control of the patients by decreasing 
CKD progression, cardiovascular morbidity, and mortal-
ity of these patients. In particular, such improvement in 
clinical outcomes and the lower rate of hospitalizations 
will also translate into a reduction of economic costs in 
monitoring CKD patients in our community.
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